Listed

Myriad Genetics Inc

MYGNNasdaqCIK 899923HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$190.7mRevenue, Q2 FY2026, three months to 2026-06-30$190.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Jul 31, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$190.7mRevenue, Q2 FY2026, three months to 2026-06-30$190.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure−10.5% on a year earlier
  • Gross margin66.6%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $127.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $190.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure−4.6 pts on a year earlier
  • Operating margin−20.4%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$38.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $190.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure+134.1 pts on a year earlier
  • Net margin−22.7%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$43.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $190.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure+132.4 pts on a year earlier
  • Diluted EPS−$0.46Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure+87.1% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$190.7mGross margin 66.6%
Diluted EPS−$0.46, Q2 FY2026
Myriad Genetics Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m213Revenue, Q3 FY2024, three months to 2024-09-30$213.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figure211Revenue, Q4 FY2024, three months to 2024-12-31$210.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure196Revenue, Q1 FY2025, three months to 2025-03-31$195.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure213Revenue, Q2 FY2025, three months to 2025-06-30$213.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure206Revenue, Q3 FY2025, three months to 2025-09-30$205.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figure210Revenue, Q4 FY2025, three months to 2025-12-31$209.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure200Revenue, Q1 FY2026, three months to 2026-03-31$200.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure191Revenue, Q2 FY2026, three months to 2026-06-30$190.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure
Gross margin%70.2%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $149.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Revenue: $213.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figure71.7%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $150.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $210.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure68.5%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $134.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Revenue: $195.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure71.2%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $151.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $213.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure69.9%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $143.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Revenue: $205.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figure70.0%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $146.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $209.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure68.7%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $137.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Revenue: $200.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure66.6%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $127.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $190.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure
Operating margin%(9.4%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$20.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Revenue: $213.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figure(18.5%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$39.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $210.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(14.8%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$29.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Revenue: $195.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure(154.5%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$329.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $213.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure(11.3%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$23.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Revenue: $205.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figure(2.7%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$5.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $209.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(15.3%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$30.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Revenue: $200.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure(20.4%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$38.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $190.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure
Net margin%(10.4%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$22.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Revenue: $213.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figure(20.2%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$42.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $210.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(0.1%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$100.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $195.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure(155.1%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$330.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $213.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure(13.3%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$27.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Revenue: $205.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figure(3.8%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$7.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $209.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(17.0%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$34.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $200.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure(22.7%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$43.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Revenue: $190.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure
Diluted EPS$ per share(0.24)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figurenot reported (Diluted EPS not reported)0.00Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure(3.57)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$3.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure(0.29)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0000899923-25-000112.Report this figurenot reported (Diluted EPS not reported)(0.36)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0000899923-26-000038.Report this figure(0.46)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0000899923-26-000072.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$824.5mGross margin 69.9%
Diluted EPS−$3.95, FY2025
Free cash flow−$151.6m, FY2022
Myriad Genetics Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m691Revenue, FY2021, twelve months to 2021-12-31$690.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0000899923-24-000018.Report this figure678Revenue, FY2022, twelve months to 2022-12-31$678.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0000899923-25-000019.Report this figure753Revenue, FY2023, twelve months to 2023-12-31$753.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure838Revenue, FY2024, twelve months to 2024-12-31$837.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure825Revenue, FY2025, twelve months to 2025-12-31$824.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure
Gross margin%not reported (Gross profit not reported)70.2%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $476.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-28, accession 0000899923-25-000019.Revenue: $678.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0000899923-25-000019.Report this figure68.6%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $517.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0000899923-26-000018.Revenue: $753.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure69.9%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $585.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0000899923-26-000018.Revenue: $837.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure69.9%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $576.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0000899923-26-000018.Revenue: $824.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure
Operating margin%(27.6%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$190.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-28, accession 0000899923-24-000018.Revenue: $690.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0000899923-24-000018.Report this figure(20.7%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$140.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-28, accession 0000899923-25-000019.Revenue: $678.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0000899923-25-000019.Report this figure(34.2%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$257.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018.Revenue: $753.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure(14.7%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$123.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018.Revenue: $837.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure(47.0%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$387.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018.Revenue: $824.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure
Net margin%(3.9%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$27.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-28, accession 0000899923-24-000018.Revenue: $690.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0000899923-24-000018.Report this figure(16.5%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$112.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0000899923-25-000019.Revenue: $678.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0000899923-25-000019.Report this figure(35.0%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$263.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018.Revenue: $753.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure(15.2%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$127.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018.Revenue: $837.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure(44.4%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$365.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0000899923-26-000018.Revenue: $824.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure
Diluted EPS$ per share(0.35)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-28, accession 0000899923-24-000018.Report this figure(1.39)Diluted EPS, FY2022, twelve months to 2022-12-31−$1.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-28, accession 0000899923-25-000019.Report this figure(3.18)Diluted EPS, FY2023, twelve months to 2023-12-31−$3.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure(1.41)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure(3.95)Diluted EPS, FY2025, twelve months to 2025-12-31−$3.95 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0000899923-26-000018.Report this figure
Free cash flow$m0.6Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $18.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-28, accession 0000899923-24-000018.Capital expenditure: $18.0m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2023-03-01, accession 0000899923-23-000011.Report this figure(152)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$106.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-28, accession 0000899923-25-000019.Capital expenditure: $45.3m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2023-03-01, accession 0000899923-23-000011.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Myriad Genetics Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$62.2m10,890,440Added+2,000,796
MILLENNIUM MANAGEMENT LLC2026-06-30$37.8m6,620,372Reduced−48,445
Vestal Point Capital, LP2026-06-30$32.7m5,735,000Added+4,087,000
STATE STREET CORP2026-06-30$28.5m4,985,060Added+561,033
D. E. Shaw & Co., Inc.2026-06-30$26.2m4,582,083Added+82,359
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$23.3m4,081,376Added+156,851
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$17.6m3,079,670Added+497,439
AQR CAPITAL MANAGEMENT LLC2026-06-30$15.8m2,766,689Added+854,393
MORGAN STANLEY2026-06-30$14.2m2,481,104Reduced−687,638
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$13.8m2,416,197Added+96,818

Recent filings

All 1,466 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Myriad Genetics Inc, recent filings
FiledFormWhat it isAccession number
2026-10-2008:36 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000899923-26-000094
2026-10-0916:16 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0000899923-26-000084
2026-09-1608:00 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000899923-26-000079
2026-07-3108:01 ET10-QQuarterly reportPeriod 2026-06-300000899923-26-000072
2026-07-3016:07 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000899923-26-000070
2026-06-2308:32 ET8-K5.02 Departure or appointment of officers or directors0000899923-26-000062
2026-06-0416:08 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0000899923-26-000059
2026-05-0606:05 ET10-QQuarterly reportPeriod 2026-03-310000899923-26-000038
2026-05-0516:07 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000899923-26-000036
2026-04-1417:01 ETDEF 14AProxy statementPeriod 2025-12-310000899923-26-000031

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 24, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
899923
Tickers
MYGN
Exchange
Nasdaq
SIC code
2835 In Vitro & In Vivo Diagnostic Substances
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer
Former names
MYRIAD GENETICS INC (to 2026-10-27)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:12 ET. Listed shows no prices and gives no investment advice.